Neutralizing TSLP with antibodies or genetically removing TSLP specifically in dermal TRMs leads to a decrease in both the number of ILC2s and their interactions with dermal TRMs in infected skin, ultimately reducing the number of dermal TRMs and promoting greater control of the infection. This evidence concerns the gene TSLP and infection.